GlaxoSmithKline (GSK +0.1%) breaks off its relationship with Impax Laboratories (IPXL -1.1%)...

GlaxoSmithKline (GSK +0.1%) breaks off its relationship with Impax Laboratories (IPXL -1.1%) regarding the experimental Parkinson's drug Rytary due to "delays in the anticipated regulatory approval and launch dates in the countries in which GSK has rights to commercialize the product." GSK was working to develop and market Rytary outside of the U.S. and Taiwan. IPXL shares have yet to fully recover from a steep decline in March stemming from FDA concerns about the testing and evaluation process for Rytary. (PR)

From other sites
Comments (1)
  • TwistTie
    , contributor
    Comments (2429) | Send Message
    I bought GSK because I like to see it trading on the London exchange when I get up in the morning (in the USA).


    Some analyst genius said it was a good idea to buy the stock for fundamental reasons.


    I think the stock has greater therapeutic value.


    By the way, I go insane trying to figure out what my dividend rate will be on these UK stocks.
    29 Apr 2013, 01:03 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs